Latest International AIDS Vaccine Initiative Stories
ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
HARRISBURG, Pa., Nov. 30 /PRNewswire-USNewswire/ -- In recognition of World AIDS Day on Dec.
SEATTLE, Nov. 30 /PRNewswire/ -- Ken Stuart, Ph.D., president and founder of Seattle Biomedical Research Institute, has been selected to present at the inaugural Partnering for Cures Conference in New York City, Dec. 1-3.
ATLANTA, Nov. 17 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S.
MIT economist Jeffrey Harris argues that while the scientific obstacles to creating an HIV vaccine are great, the lack of commercial incentive poses a major problem.
ROCKVILLE, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S. Military HIV Research Program (MHRP), in coordination with the Rockville Vaccine Assessment Clinic (RVAC), is holding an informational event about HIV vaccine research on Thursday, October 29, 2009 from 6:00-7:30 p.m. at 1600 E.
ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
ATLANTA, Oct. 15 /PRNewswire-FirstCall/ -- Today, Formatech, Inc. announced that GeoVax Labs, Inc.'s (OTC Bulletin Board: GOVX) ("GeoVax") ("Company") HIV/AIDS vaccine will be the first clinical candidate that is formulated and filled under its Fillanthropy Program.
The promising results of a six-month clinical trial of an AIDS vaccine have been called into question, according to two published accounts on Science magazineâ€™s Web site and in The Wall Street Journal.
- a meat pie that is usually eaten at Christmas in Quebec